Skip to content

Evozyne vs Manifold Bio

Evozyne logo

Evozyne

Evozyne designs novel therapeutic proteins with generative AI to solve immunology’s toughest challenges

55 employees · est. 2020 · Chicago, United States

VS
Manifold Bio logo

Manifold Bio

Organism-scale intelligence, designed in vivo

81 employees · est. 2020 · Boston, United States

Side-by-Side Comparison

Evozyne Manifold Bio
Founded
2020 2020
Headquarters
Chicago, United States Boston, United States
Employees
55 81
Industry
Biotechnology, Pharmaceutical Biotechnology, Health Care, Health and Wellness
Funding Stage
Series B Series A
Total Funding
$144.36M $60.40M
Funding Rounds
4 5
Services
AI-native Protein Design, Protein Synthesis and Testing, Therapeutic Protein Development, Immunology Pipeline Advancement AI-powered protein design, In vivo biologics validation, Multiplexed screening experiments, Therapeutic pipeline development, Partner collaborations
Target Customers
Patients with High Unmet Need in Immune-Mediated Diseases, Healthcare Providers, Pharmaceutical Companies Biopharma companies, Medical researchers, Healthcare institutions, Biotechnology partners, Academic institutions
Taxonomy
Generative AIDrug DiscoveryProtein DesignTherapeutic DiscoveryMolecular ScaleNovel Protein Therapeutics +5 AI-guided TherapeuticsIn Vivo Discovery PlatformProtein DesignMultiplexed Data GenerationVirtual Organism DevelopmentTherapeutics Pipeline +8
Website
evozyne.com manifold.bio
Evozyne logo

About Evozyne

Evozyne, founded in 2020, is at the forefront of the Biotechnology and Pharmaceutical industries with its innovative approach to drug development. The company's slogan, "Generative AI-powered drug discovery platform and product development," encapsulates its mission to design novel protein therapeut...

Manifold Bio logo

About Manifold Bio

Manifold Bio, founded in 2020, is a cutting-edge platform therapeutics company headquartered in the United States. The company is known for its bold tagline: "Organism-scale intelligence, designed in vivo". It specializes in leveraging biotechnology, healthcare, health and wellness, and pharmaceutic...

Also comparing in this category

Comparing more than these two?

Get Evozyne, Manifold Bio and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Evozyne compare?

A PDF of Evozyne and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Evozyne was founded in 2020, based in Chicago, United States, with 55 employees. Evozyne, founded in 2020, is at the forefront of the Biotechnology and Pharmaceutical industries with its innovative approach to drug development. The company's slogan, "Generative AI-powered drug dis. Manifold Bio was founded in 2020, based in Boston, United States, with 81 employees. Manifold Bio, founded in 2020, is a cutting-edge platform therapeutics company headquartered in the United States. The company is known for its bold tagline: "Organism-scale intelligence, designed in.
Evozyne has raised $144.36M and Manifold Bio $60.40M. Latest stage: Evozyne Series B, Manifold Bio Series A.
Both work in Biotechnology and Pharmaceutical and list protein design among their focus areas.

Compare Evozyne with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Evozyne on 15 Jun 2026, and Manifold Bio on 8 Nov 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout